CLN3基因在卵巢浆液性癌中的表达

Expression of CLN3 Gene in Ovarian Serous Cancer

[目的]探讨CLN3基因在卵巢浆液性囊腺癌中的表达特点及与其生物学行为的关系。[方法]采用半定量RT-PCR方法和Western blot方法检测45例卵巢浆液性肿瘤(良性浆液性肿瘤11例,交界性肿瘤11例,浆液性癌23例)和12例正常卵巢组织中CLN3基因表达情况。[结果]卵巢浆液性囊腺癌组织中CLN3mRNA表达为3.04±0.58,交界性卵巢浆液性囊腺瘤组织中表达为1.63±0.43,均明显高于正常卵巢组织和卵巢浆液性囊腺瘤(P<0.01);卵巢浆液性囊腺癌组织CLN3mRNA表达高于交界性卵巢浆液性囊腺瘤(P<0.01);卵巢浆液性囊腺癌患者Ⅰ/Ⅱ期与Ⅲ/Ⅳ期、G1/G2与G3及有无腹水间比较差异有显著性(P<0.05)。[结论]CLN3基因与卵巢浆液性癌的发生发展和预后可能有关,可作为卵巢浆液性癌重要的生物学标志物。

[Purpose] To explore the relationship between expression of CLN3 gene and its bi- ological behaviors in ovarian serous cancer. [Methodsl The expression of CLN3 in 45 cases with ovarian serous tumor （23 cases with ovarian serous cancer, 11 cases with borderline ovarian serous tumor, 11 cases with benign serous tumor） and 12 cases of normal ovarian tissue were detected by reverse-transcription polymerase chain reaction （RT-PCR） and Western blot methods. [Results] The expression of CLN3 mRNA was 3.04±0.58 in ovarian serous cancer and 1.63±0.43 in borderline ovarian serous tumor. The expressions of CLN3 mRNA in ovarian serous cancer and borderline ovarian serous tumor were significantly higher than those in benign ovarian serous tumor and nolanal ovarian tissue （P〈0.01）. The expression of CLN3 mRNA in ovarian serous cancer was higher than that in borderline ovarian serous tumor （P〈 0.01）. There was significantly difference between stage I/Ⅱ and Ⅲ-/Ⅳ, G1/G2 and G3, with and without ascites （P〈0.05）. [Conclnsion] CLN3 might be related to the carcinogenesis and prognosis of ovarian serous cancer and become an important biological marker for ovarian